Description
Fluzone High-Dose Quadrivalent (QIV) 0.7ml Prefilled Syringes - Pack of 5
This is a restricted schedule drug. Only to be sold to medical professionals. You will be required to provide your APHRA Registration Number/Scheduled Drug License.
A high-dose, inactivated quadrivalent influenza vaccine designed to help protect older adults each flu season. Registered in Australia for use in adults 60 years and older and supplied as five single-dose (0.7 mL) prefilled syringes for intramuscular injection. The Australian Immunisation Handbook+2Therapeutic Goods Administration (TGA)+2
Key features
-
High-dose formulation: 240 µg total haemagglutinin (HA) per 0.7 mL dose (60 µg HA from each of the 4 WHO/AIVC-recommended strains). Split-virion, egg-based, inactivated vaccine. Therapeutic Goods Administration (TGA)
-
Who it’s for: Registered for adults ≥60 years; use should follow the Australian Immunisation Handbook and local recommendations. The Australian Immunisation Handbook
-
Dose & route: Single 0.7 mL dose intramuscularly (IM) each influenza season, per official guidance. Shake before use; single-use syringe. Therapeutic Goods Administration (TGA)
-
Pack size: Box of 5 prefilled syringes (0.7 mL each). (Note: multiple ARTG-listed pack configurations exist; check local supply details.) Therapeutic Goods Administration (TGA)
Composition & excipients
Each 0.7 mL dose contains 60 µg HA of each of the four recommended strains (total 240 µg). Excipients include sodium chloride, sodium phosphates and octoxinol-9. May contain traces of formaldehyde (≤140 µg) and ovalbumin (≤1 µg); no preservative or antibiotics used in manufacture. Therapeutic Goods Administration (TGA)
Storage & handling
-
Store at 2–8 °C (refrigerate). Do not freeze. Discard if frozen. Maintain cold chain. Therapeutic Goods Administration (TGA)
Administration notes (for healthcare professionals)
-
IM administration only (preferably deltoid).
-
Do not mix with other vaccines in the same syringe.
-
Inspect visually; do not use if discoloured or particulate matter is present. Therapeutic Goods Administration (TGA)
Regulatory information
-
ARTG ID: 320962 • Sponsor: Sanofi-Aventis Australia Pty Ltd • Schedule: S4 (Prescription Only Medicine). Therapeutic Goods Administration (TGA)+1
Important: This information is intended for Australian healthcare professionals. Always consult the current Product Information and the Australian Immunisation Handbook when selecting and administering vaccines.
